INM vs. ATNF, NBSE, PRFX, HSTO, GLMD, BPTH, PBLA, LSDI, GRI, and QLGN
Should you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include 180 Life Sciences (ATNF), NeuBase Therapeutics (NBSE), PainReform (PRFX), Histogen (HSTO), Galmed Pharmaceuticals (GLMD), Bio-Path (BPTH), Panbela Therapeutics (PBLA), Lucy Scientific Discovery (LSDI), GRI Bio (GRI), and Qualigen Therapeutics (QLGN). These companies are all part of the "pharmaceutical preparations" industry.
InMed Pharmaceuticals (NASDAQ:INM) and 180 Life Sciences (NASDAQ:ATNF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, community ranking, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.
In the previous week, InMed Pharmaceuticals and InMed Pharmaceuticals both had 1 articles in the media. 180 Life Sciences' average media sentiment score of 1.00 beat InMed Pharmaceuticals' score of -1.00 indicating that 180 Life Sciences is being referred to more favorably in the news media.
InMed Pharmaceuticals received 6 more outperform votes than 180 Life Sciences when rated by MarketBeat users. However, 66.67% of users gave 180 Life Sciences an outperform vote while only 47.06% of users gave InMed Pharmaceuticals an outperform vote.
180 Life Sciences has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -115.76%. InMed Pharmaceuticals' return on equity of -54.31% beat 180 Life Sciences' return on equity.
20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.1% of 180 Life Sciences shares are owned by institutional investors. 1.4% of InMed Pharmaceuticals shares are owned by insiders. Comparatively, 4.1% of 180 Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
InMed Pharmaceuticals has higher revenue and earnings than 180 Life Sciences.
InMed Pharmaceuticals has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500.
Summary
InMed Pharmaceuticals beats 180 Life Sciences on 6 of the 11 factors compared between the two stocks.
Get InMed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InMed Pharmaceuticals Competitors List
Related Companies and Tools
